Clinical Trials Logo

Clinical Trial Summary

This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days of treatment. The two periods consist of: 1. A 3-week screening period that includes a TG qualifying period, and 2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment period. Subjects will return to the study site for a follow-up visit 2 weeks after the last dose. Approximately 50 subjects will be randomized at approximately 15-30 centres in USA.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05889156
Study type Interventional
Source NorthSea Therapeutics B.V.
Contact Brandy Dupee
Phone +31 (0) 35 760 65 05
Email brandy.dupee@northseatherapeutics.com
Status Recruiting
Phase Phase 2
Start date June 30, 2023
Completion date February 29, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05962372 - Culturally Adapted Dietary Clinical Trial in PR N/A
Completed NCT00833976 - Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia Phase 4
Completed NCT03975556 - Culturally-Adapted Diet for Puerto Rican Adults N/A